<DOC>
	<DOCNO>NCT01392612</DOCNO>
	<brief_summary>We hypothesize effect erythropoietin may reflect change thromboxane B2 ( TXB2 ) endothelial cell function . Six male six female subject receive recombinant human epoetin alpha ( Erypo® ) intravenously ( 300 Units per kg ) . Biomarker level assess baseline 4 , 24 , 48 72 hour administration .</brief_summary>
	<brief_title>Erythropoietin Platelet Activation Markers</brief_title>
	<detailed_description>Introduction : Erythropoietin ( EPO ) enhance formation red blood cell also affect thrombopoiesis platelet function . We hypothesize effect erythropoietin may reflect change thromboxane B2 ( TXB2 ) endothelial cell function . Methods : Six male six female subject receive recombinant human epoetin alpha ( Erypo® ) intravenously ( 300 Units per kg ) . Biomarker level assess baseline 4 , 24 , 48 72 hour administration . Results : Epoetin alpha increase TXB2 level , reach significance 48h ( 2.5- fold increase : 6.6±5ng/mL vs. 15±9ng/mL ; p=0.044 ) remain level 72h . In line , epoetin alpha increase E-selectin level 25 % already 24h ( 39±21ng/ml vs. 49±26ng/ml ; p &lt; 0.001 ) stay level 72h ( p &lt; 0.001 ) . The raise platelet activation marker correspond 2-fold increase reticulocyte count ( 81±17G/L vs. 43±10G/L ; p &lt; 0.001 ) 9 % increase platelet count 72h ( 224±45G/L vs. 244±52G/L ; p=0.005 ) . Thrombomodulin von Willebrand factor concentration significantly alter epoetin alpha . Interestingly , gender difference baseline level E-selectin thrombomodulin observe . E-selectin thrombomodulin level double men compare woman ( 51±24ng/mL 28±10ng/mL ; p=0.025 30±5ng/mL vs. 16±5ng/mL ; p=0.002 , respectively ) . Conclusion : Epoetin alpha increase level platelet activation marker . Further study need investigate whether measurement TXB2 E-selectin level might useful estimation thromboembolic risk EPO-therapy .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Healthy male female volunteer . Age 1840 year . Body mass index 1727 . Normal haemoglobin level ( Hb males 13.518g/dL , female 1216g/dL ) . Reticulocyte count within reference value ( 32110G/L ) . SIron within reference value ( male 60150µg/dl , female 40150µg/dL ) . Serum ferritin within reference value ( female 10140µg/L , male 20280µg/L ) . CRP within reference value ( &lt; 1,0mg/dL ) . Signed informed consent . Normal finding medical history physical examination unless investigator considers abnormality clinically irrelevant study . Woman child bear potential must agree practice effective barrier method birth control . Smoking . Regular use medication food supplement contain iron . Abuse alcoholic beverage drug . Participation clinical trial 3 week precede study . Foreseen inability attend schedule study visit . Deficiency folate ( &lt; 3.4nmol/L ) vitamin B12 ( &lt; 118pmol/L ) ( reevaluation supplementation allow ) . Evidence hypertension , pathologic hyperglycemia , hyperlipidemia . AST and/or ALAT &gt; 3xULN ( AST male &gt; 105U/L , female &gt; 93U/ ; ALAT males &gt; 135U/L , female &gt; 102U/L ) . Symptoms clinically relevant illness 3 week prior first study day . History presence gastrointestinal , liver kidney disease , condition know interfere distribution , metabolism excretion erythropoietin . Blood donation previous 3 week prior first study day . History hypersensitivity erythropoietin . Pregnancy lactation period . Any medical condition , opinion investigator , would interfere safety subject interference objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>thrombosis</keyword>
	<keyword>hypertension</keyword>
	<keyword>gender</keyword>
	<keyword>endothelium</keyword>
</DOC>